Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | LPL | P06858 | 7/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19933583 | 0.92 | DGAT1 (0.55) | DGAT1LPLLIPGPDGFRBKDR | |
| SCHEMBL18015506 | 0.90 | DGAT1 (0.60) | DGAT1LPLLIPGEGFRPDGFRB | |
| SCHEMBL21125803 | 0.87 | DGAT1 (0.57) | DGAT1LPLLIPGEGFRPDGFRB | |
| SCHEMBL19933806 | 0.83 | MAP4K4 (0.43) | DGAT1MAP4K4LPLLIPGTGFBR1 | |
| SCHEMBL21125909 | 0.83 | DGAT1 (0.67) | DGAT1LPLLIPGPDGFRBKDR | |
| SCHEMBL18015426 | 0.81 | DGAT1 (0.50) | DGAT1MAP4K4LPLLIPG | |
| SCHEMBL15747792 | 0.80 | DGAT1 (0.57) | DGAT1LPLLIPG | |
| SCHEMBL15747843 | 0.79 | DGAT1 (0.57) | DGAT1LPLLIPGPDGFRBKDR | |
| SCHEMBL19933582 | 0.79 | DGAT1 (0.62) | DGAT1LPLLIPGPDGFRBKDR | |
| SCHEMBL19933719 | 0.78 | DGAT1 (0.49) | DGAT1LPLLIPGTGFBR1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3507294-B1 | BINUCLEAR AND TRINUCLEAR METAL COMPLEXES COMPOSED OF TWO INTER-LINKED TRIPODAL HEXADENTATE LIGANDS FOR USE IN ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2021-02-24 | — | — | EP | disclosed |
| US-10889604-B2 | Binuclear and trinuclear metal complexes composed of two inter-linked tripodal hexadentate ligands for use in electroluminescent devices | MERCK PATENT GMBH | 2021-01-12 | — | — | US | disclosed |
| US-20190202851-A1 | BINUCLEAR AND TRINUCLEAR METAL COMPLEXES COMPOSED OF TWO INTER-LINKED TRIPODAL HEXADENTATE LIGANDS FOR USE IN ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2019-07-04 | — | — | US | disclosed |
| WO-2018041769-A1 | BINUCLEAR AND TRINUCLEAR METAL COMPLEXES COMPOSED OF TWO INTER-LINKED TRIPODAL HEXADENTATE LIGANDS FOR USE IN ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202851-A1 | BINUCLEAR AND TRINUCLEAR METAL COMPLEXES COMPOSED OF TWO INTER-LINKED TRIPODAL HEXADENTATE LIGANDS FOR USE IN ELECTROLUMINESCENT DEVICES | PARN, PUF60, PARG | DGAT1 2586/4885MAP4K4 3458/4885LPL 4558/4885 |
| US-10889604-B2 | Binuclear and trinuclear metal complexes composed of two inter-linked tripodal hexadentate ligands for use in electroluminescent devices | PARN, PUF60, PARG | DGAT1 2586/4885MAP4K4 3458/4885LPL 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.